Skip to main content

Table 6 EHR cohort (n = 367): Concomitant medication at index

From: Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study

Treatment

n (%)

ASTHMA MEDICATIONS

367 (100.0%)

 Inhaled corticosteroids (ICS)

215 (58.6)

 Long-acting ß2-agonists (LABA)

124 (33.8)

 ICS/LABA combination

208 (56.7)

 Adrenergic in combination with anticholinergics

5 (1.4)

 Short acting

5 (1.4)

 Long acting

NA

 Leukotriene modifiers (LTRA)

113 (30.8)

 Methylxanthines

4 (1.1)

 Anti-IgE treatment

NA

 Short-acting ß2-agonists (SABA)

256 (69.8)

 Systemic corticosteroids (OCS)

367 (100.0)

 Anticholinergics

21 (5.7)

  - Short acting

9 (2.5)

  - Long acting

13 (3.5)

 Omalizumab

NA

 PD4 antagonists

NA

 N-acetylcysteine

126 (34.3)

Cardiovascular medications (ANY)

155 (42.2)

 Anti-dyslipidaemias

50 (13.6)

 Statins

48 (13.1)

 Fibrates

1 (0.3)

 Anti-hypertensives

90 (24.5)

 Beta-blockers

47 (12.8)

 ACEs

29 (7.9)

 ARBs

44 (12.0)

Other medications

111 (30.2)

 Antibiotics

169 (46.0)

 Anti-virus

11(3.0)

 Anti-allergy

3 (0.8)

 Cough and cold

223 (60.8)

 Antihistamines

201 (54.8)

 Nasal corticosteroids

162 (44.1)

 Antidepressant

65 (17.7)

 Hypnotics

46 (12.5)

 Antianxiety

63 (17.2)

 Bifosfonates

10 (2.7)

 Calcium D vitamine

2 (0.5)

  1. NA = value not found or zero